There are a handful of ways to visualize selectivity among kinase inhibitors after you’ve had them Profiled.
The gold standard has become the Ambit panel:
(from the Nature Biotech paper)
A simple chart will get the job done:
(INNO-406 / NS-187, from Blood 05, 3948)
or a heat map like Amphoras’:
If you prefer a reductionist approach you’ve always been able to take it down to a single number with fold shift from its nearest neighbor.
And now it looks like there may be a statistically more meaningful number with the recent J Med Chem on applying the Gini Coefficient to kinase inhibitor selectivty. In case you missed it, check out the spreadsheet in the supporting info.
The gold standard has become the Ambit panel:
(from the Nature Biotech paper)
A simple chart will get the job done:
(INNO-406 / NS-187, from Blood 05, 3948)
or a heat map like Amphoras’:
If you prefer a reductionist approach you’ve always been able to take it down to a single number with fold shift from its nearest neighbor.
And now it looks like there may be a statistically more meaningful number with the recent J Med Chem on applying the Gini Coefficient to kinase inhibitor selectivty. In case you missed it, check out the spreadsheet in the supporting info.
I think everybody knows that the Kd’s don’t make any sense, and that Upstate isn’t far behind on the numbers game.
Look at the problems of p38 inhibitors
And how will GSK-3 inhibitors, for Alzhimer’s, look on such a diagram?